{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:17:28Z","timestamp":1768565848100,"version":"3.49.0"},"posted":{"date-parts":[[2023,11,6]]},"group-title":"Oncology","reference-count":29,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,11,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>This study aimed to validate the chemotherapy-induced alopecia distress scale (CADS) in a diverse English-speaking population and patients with endocrine treatment- induced alopecia (EIA).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Chemotherapy and endocrine therapy commonly cause alopecia in breast cancer patients, leading to significant psychological and social challenges. The CADS was developed to assess the psychosocial impact of alopecia, but its generalizability beyond Korean patients requires further investigation.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>\n                    Data from the CHANCE study (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02530177\">NCT02530177<\/jats:ext-link>\n                    ), which focused on non-metastatic breast cancer, was used. The cohort included 256 patients, and CADS data were collected at baseline, six months after chemotherapy completion, or 12 months after initiating endocrine therapy. The CADS questionnaire comprised 17 items covering physical and emotional health, daily activities, and relationships. Reliability was assessed using Cronbach\u2019s alpha, and responsiveness was measured by effect size.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The CADS exhibited good reliability, with a Cronbach\u2019s alpha of 0.91 for the overall score, indicating acceptable internal consistency in both chemotherapy (0.89) and endocrine therapy (0.86) groups. Longitudinal responsiveness was supported by an effect size of 0.49 between decreasing satisfaction with hair growth and increasing emotional distress. Cross-sectional validity was confirmed, with effect sizes of 0.91 and 0.92 for satisfaction with hair growth and emotional and activity domains, respectively.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The CADS is a valid and responsive tool for assessing the psychosocial impact of chemotherapy-induced alopecia and endocrine treatment-induced alopecia in a diverse Western patient population.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2023.11.05.23298093","type":"posted-content","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T16:35:10Z","timestamp":1699288510000},"source":"Crossref","is-referenced-by-count":0,"title":["Validation and Responsiveness of the English version of the Chemotherapy-Induced Alopecia Distress Scale (CADS) in Breast Cancer Patients"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5411-5661","authenticated-orcid":false,"given":"L.","family":"Kraehenbuehl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. S.","family":"Bang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. F.","family":"Ketosugbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Hay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujata","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Goldfarb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4818-3710","authenticated-orcid":false,"given":"M. E.","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2023110910150743000_2023.11.05.23298093v1.1","doi-asserted-by":"crossref","unstructured":"Tr\u00fceb RM . Chemotherapy-induced alopecia. Seminars in cutaneous medicine and surgery. 28. No longer published by Elsevier; 2009:11\u201314.","DOI":"10.1016\/j.sder.2008.12.001"},{"key":"2023110910150743000_2023.11.05.23298093v1.2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0184"},{"key":"2023110910150743000_2023.11.05.23298093v1.3","doi-asserted-by":"crossref","unstructured":"Boland V , Brady A-M , Drury A . The physical, psychological and social experiences of alopecia among women receiving chemotherapy: An integrative literature review. European Journal of Oncology Nursing 2020; 49: 101840.","DOI":"10.1016\/j.ejon.2020.101840"},{"key":"2023110910150743000_2023.11.05.23298093v1.4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5394.2001.96007.x"},{"issue":"6","key":"2023110910150743000_2023.11.05.23298093v1.5","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/jamadermatol.2018.0454","article-title":"Endocrine Therapy\u2013Induced Alopecia in Patients With Breast Cancer","volume":"154","year":"2018","journal-title":"JAMA Dermatology"},{"key":"2023110910150743000_2023.11.05.23298093v1.6","doi-asserted-by":"publisher","DOI":"10.5301\/tj.5000376"},{"key":"2023110910150743000_2023.11.05.23298093v1.7","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2744-2"},{"key":"2023110910150743000_2023.11.05.23298093v1.8","doi-asserted-by":"publisher","DOI":"10.1002\/pon.1245"},{"key":"2023110910150743000_2023.11.05.23298093v1.9","doi-asserted-by":"publisher","DOI":"10.1002\/pon.3531"},{"key":"2023110910150743000_2023.11.05.23298093v1.10","unstructured":"CTEP N. CTCAE v5.0. 2020. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf."},{"key":"2023110910150743000_2023.11.05.23298093v1.11","doi-asserted-by":"crossref","unstructured":"Basch E , Reeve BB , Mitchell SA et al. Development of the National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JNCI: Journal of the National Cancer Institute 2014; 106 (9).","DOI":"10.1093\/jnci\/dju244"},{"issue":"3","key":"2023110910150743000_2023.11.05.23298093v1.12","first-page":"219","article-title":"HairdexEin Instrument zur Untersuchung der krankheitsbezogenen Lebensqualit\u00e4t bei Patienten mit Haarerkrankungen","volume":"52","year":"2001","journal-title":"Der Hautarzt"},{"key":"2023110910150743000_2023.11.05.23298093v1.13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2001.00229.x"},{"issue":"1","key":"2023110910150743000_2023.11.05.23298093v1.14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ijwd.2017.11.007","article-title":"Review of quality of life studies in women with alopecia","volume":"4","year":"2018","journal-title":"International Journal of Women\u2019s Dermatology"},{"key":"2023110910150743000_2023.11.05.23298093v1.15","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2648.2000.01295.x"},{"key":"2023110910150743000_2023.11.05.23298093v1.16","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt476"},{"issue":"9","key":"2023110910150743000_2023.11.05.23298093v1.17","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1007\/s00520-019-05284-0","article-title":"A Chinese version of the chemotherapy-induced alopecia distress scale based on reliability and validity assessment in breast cancer patients","volume":"28","year":"2020","journal-title":"Support Care Cancer"},{"key":"2023110910150743000_2023.11.05.23298093v1.18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt476"},{"key":"2023110910150743000_2023.11.05.23298093v1.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.02.006"},{"key":"2023110910150743000_2023.11.05.23298093v1.20","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-005-1524-9"},{"issue":"15_suppl","key":"2023110910150743000_2023.11.05.23298093v1.21","doi-asserted-by":"crossref","first-page":"e12500","DOI":"10.1200\/JCO.2018.36.15_suppl.e12500","article-title":"The CHANCE study: A prospective, longitudinal study of chemotherapy and hormonal therapy induced hair changes and alopecia, skin aging and nail changes in women with non-metastatic breast cancer","volume":"36","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"2023110910150743000_2023.11.05.23298093v1.22","first-page":"695","article-title":"Using cross-cultural input to adapt the Functional Assessment of Chronic Illness Therapy (FACIT) scales. Acta oncologica (Stockholm","volume":"38","year":"1999","journal-title":"Sweden"},{"key":"2023110910150743000_2023.11.05.23298093v1.23","doi-asserted-by":"publisher","DOI":"10.3102\/10769986027004335"},{"key":"2023110910150743000_2023.11.05.23298093v1.24","doi-asserted-by":"crossref","unstructured":"Aiken LR . Book Reviews : Measuring Educational Achievement by Robert L. Ebel . Englewood Cliffs, N. J. : Prentice-Hall , 1965. pp. xii + 481. Educational and Psychological Measurement 1965; 25 (4): 1167\u20131169.","DOI":"10.1177\/001316446502500428"},{"key":"2023110910150743000_2023.11.05.23298093v1.25","doi-asserted-by":"crossref","unstructured":"van Zyl LE , Ten Klooster PM . Exploratory Structural Equation Modeling: Practical Guidelines and Tutorial With a Convenient Online Tool for Mplus. Front Psychiatry 2021; 12: 795672.","DOI":"10.3389\/fpsyt.2021.795672"},{"key":"2023110910150743000_2023.11.05.23298093v1.26","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30369"},{"key":"2023110910150743000_2023.11.05.23298093v1.27","unstructured":"Food U, Administration D. The voice of the patient. A series of reports from the US Food and Drug Administration\u2019s (FDA\u2019s) Patient-Focused Drug Development Initiative. Lung Cancer Available from: http:\/\/waybackarchive-itorg\/7993\/20171114193841\/ https:\/\/www.fdagov\/ForIndustry\/UserFees\/PrescriptionDrugUserFee\/ucm353273htm Accessed February 2018; 28."},{"key":"2023110910150743000_2023.11.05.23298093v1.28","doi-asserted-by":"publisher","DOI":"10.4103\/sja.SJA_203_17: 10.4103\/sja.SJA_203_17"},{"key":"2023110910150743000_2023.11.05.23298093v1.29","doi-asserted-by":"publisher","DOI":"10.1007\/BF02294210"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.11.05.23298093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:44:30Z","timestamp":1768506270000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2023.11.05.23298093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,6]]},"references-count":29,"URL":"https:\/\/doi.org\/10.1101\/2023.11.05.23298093","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1007\/s00520-024-08564-6","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2023,11,6]]},"subtype":"preprint"}}